¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"lethal multiple pterygium syndrome"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
¿µ¹® withdrawal syndrome ÇÑ±Û ±Ý´ÜÁõÈıÙ
¼³¸í   
  ¾ËÄÚ¿Ã, ¸¶¾à, ¹ÙºñÅõ¸£»ê°è ÃÖ¸é¾à µîÀÇ ¾à¹°À» Àå±â°£ º¹¿ëÇÏ¿© ¾à¹°ÀÌ ¾øÀ̴ °ßµô ¼ö ¾ø°ÔµÈ µÚ, ±× ¾à¹°À» ÁßÁöÇÑ °æ¿ì¿¡ ³ªÅ¸³ª´Â, °íÅëÀÌ ¼ö¹ÝµÇ´Â ½ÅüÀû Áõ»óÀ» ¸»ÇÑ´Ù. ¿¬¼Ó º¹¿ëÀÇ ±â°£¿¡ µû¶ó Áõ»óÀÌ ¹«°Å¿öÁø´Ù. Åë»óÀûÀ¸·Î ±¸Åä, ¼³»ç, Ç÷¾Ð»ó½Â, ºü¸¥¸Æ, ¶¡³², È¥¼ö µîÀÇ Áõ»óÀÌ ³ªÅ¸³­´Ù.
  
  
¿µ¹® organic brain syndrome ÇÑ±Û ±âÁúÀû ³úÁõÈıº
¼³¸í   
  ³úÀÇ ±âÁúÀûÀÎ(organic-:ÀÌ ¸»Àº ±â´ÉÀûÀÎ(functional)¿¡ ¹ÝÇϴ ¸»·Î½á) ¸ðµç °Ë»ç¸¦ ½ÃÇàÇϸ頾 ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö Àִٴ ¶æÀÌ´Ù. ¹Ù²Ù¾î ¸»Çϸé, ±â´ÉÀûÀΠÀ̻󿡠ÀÇÇÑ ³úÁõÈıºÀº ¾î¶°ÇÑ °Ë»ç·Îµµ ÀÌ»óÀ» ¹ß°ßÇÒ ¼ö ¾øÀ¸³ª ºÐ¸íÈ÷ È¯ÀÚ¿¡°Ô ÀÌ»óÁõ»óÀÌ ³ªÅ¸³µÀ» ¶§ À̸¦ ¹­¾î¼­ ¸»ÇÑ´Ù. À̻󿡠ÀÇÇØ ½Å°æÇÐÀûÀΠÀÌ»óÀ» ³ªÅ¸³»´Â ÀÏ·ÃÀÇ º´ÀûÇö»óÀ» ¸ðµÎ ÅëÆ²¾î ¸»ÇÑ´Ù. ÀÌ º´Àº ÈçÈ÷ º¸¾Æ ¸¶Ä¡ Á¤½Åº´È¯ÀÚó·³ ¸»À» È¾¼³¼ö¼³Çϰí, ¾Ë¾ÆµéÀ» ¼ö ¾ø´Â ¸»À» Çϸç, ¶§·Î´Â ´Ù¸¥ »ç¶÷¿¡°Ô °ø°ÝÀûÀΠ¼ºÇâÀ» ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×¸®°í ´Ù¸¥ »ç¶÷°ú µµÀúÈ÷ ±³·ù¸¦ ÇÒ ¼ö ¾ø´Â Á¤¼­¸¦ ³ªÅ¸³»±âµµ ÇÑ´Ù. ±×·¯³ª, ÀÌ º´ÀÌ ´Ù¸¥ Á¤½Åº´°ú ±¸º°µÇ´Â Æ¯Â¡ÀûÀΠÁõ»óÀº ¸ÕÀú, ÀǽÄÀǠȥŹÀÌ µ¿¹ÝµÇ´Â °æ¿ì°¡ ¸¹°í, ¶ÇÇÑ ±× Áõ»óÀÇ Á¤µµ°¡ º¯ÇѴٴ °ÍÀÌ´Ù. Áï, ¾ÆÄ§¿¡´Â Á¤»óÀûÀΠÇൿÀ» ÇÏ´Ù°¡ ¿ÀÈİ¡ µÇ¸é, ÀǽÄÀÌ Èå·ÁÁö¸é¼­ ¸»À» È¾¼³¼ö¼³ÇÑ´Ù¸é, À̴ ±âÁú¼º³úÁõÈıºÀÏ °¡´É¼ºÀÌ ³ô´Ù.
¿µ¹® Down syndrome ÇÑ±Û ´Ù¿îÁõÈıº
¼³¸í   
  »ç¶÷ÀÇ 46°³ ¿°»öü Áß Á¦ 21¹ø ¿°»öüÀÇ ¼ö°¡ 1°³ ´õ ¸¹¾ÆÁö¹Ç·Î½á ³ªÅ¸³ª´Â º´ÀÌ´Ù. È¯ÀÚÀÇ »ý±è»õ°¡ ¸¶Ä¡ ¸ù°í »ç¶÷°ú ´à¾Ò´Ù ÇÏ¿© ÀÏ¸í ¸ù°íÁõ(mongolism)À̶ó°í ÇÏ¿´À¸³ª À߸øµÈ À̸§ÀÌ´Ù. ÀÌ º´Àº ¹Ýµå½Ã 21¹ø ¿°»öü°¡ 3°³°¡ µÇ´Â °æ¿ìÀ̿ܿ¡µµ 21¹ø ¿°»öüÀÇ ÀϺκÐÀÌ ´Ù¸¥ ¿°»öüÀÇ ÀϺκаú ±³È¯ÀÌ µÇ´Â translocationÇü µîÀÇ ´Ù¸¥ ¿°»öüÀ̻󿡼­µµ º¼ ¼ö°¡ ÀÖ´Ù. ¹ß»ý ºóµµ´Â Ãâ»ý¾Æ 700~1000¸íÁß 1¸í ²Ã·Î ³ªÅ¸³ª¸ç, ¿°»öü À̻󺴠Áß¿¡ °¡Àå ¸¹Àº °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ´Ù. ÀÌ º´ÀÇ ¹ß»ýºóµµ´Â »ê¸ðÀÇ Ãâ»ê¿¬·É°ú ¹ÐÁ¢ÇÑ °ü°è°¡ ÀÖ¾î, 35¼¼ ÀÌÈİ¡ µÇ¸é ±âÇÏ ±Þ¼öÀûÀ¸·Î ÀÌ ÁúȯÀÚÀÇ Ãâ»ê¼ö°¡ Áõ°¡ÇÑ´Ù. ÀϹÝÀûÀ¸·Î ÀÌ Áúȯ¿¡ À־ ¾à 3ºÐÀÇ 1Àº ¸ðÄ£ÀÇ Ãâ»ê¿¬·É¿¡ ÀÇÁ¸ÇÏÁö ¾Ê°í, ³ª¸ÓÁö ¾à 3ºÐÀÇ 2´Â ¸ðÄ£ÀÇ ¿¬·É°ú Á÷Á¢ °ü·ÃÀÌ Àִ °ÍÀ¸·Î º¸°í ÀÖ´Ù. Áø´ÜÀº Æ¯Â¡ÀûÀΠ»ý±è»õ, Áï ¸ù°í »ç¶÷°°ÀÌ ´«²¿¸®°¡ À§·Î Ä¡ÄÑÁ® ÀÖ°í ´«°ÅÇ®ÀÌ µÎ²¨¿ì¸ç ÄàµîÀÌ ³·Àº Æ¯Â¡ÀûÀΠ¾ó±¼ ¸ð½À, ¶ÇÇÑ ±ÙÀ°ÀÇ ±äÀåµµ°¡ ÀúÇϵǰí Á¥À» ºü´Â Èû°ú ¿ïÀ½ ¼Ò¸®°¡ ¾àÇϸ砼չٴÚÀÇ Á¿츦 °¡¸£´Â ÇÑÁÙÀÇ ¼Õ±Ý(¿ø¼þÀ̿͠°°Àº ÇüÅÂÀÌ´Ù) µîÀǠƯ¡ÀûÀΠ¼Ò°ß¿¡ ÀÇÇØ º¸Á¶Áø´ÜÀ» Çϰí ÃÖÁ¾ÀûÀ¸·Î ¿°»öü ºÐ¼®¿¡ ÀÇÇØ È®ÁøÀ» ÇÑ´Ù. ÀÌ ´Ù¿îÁõÈıºÀǠȯÀڴ ´ë°³ Áö´ÉÀÌ ÀúÇϵǾî ÀÖ°í, ¿©·¯ °¡Áö Á¾·ùÀÇ ¼±Ãµ¼º ½ÉÀå±âÇüÀ» ¸¹ÀÌ µ¿¹ÝÇϰí ÀÖ´Ù.
¿µ¹® dumping syndrome ÇÑ±Û ´ýÇÎÁõÈıº
¼³¸í   
  ºÎºÐÀû À§ÀýÁ¦¼ú ¶Ç´Â À§ºóâÀÚ¿¬°á¼úÀ» ¹ÞÀº È¯ÀÚ¿¡°Ô¼­ À½½ÄÀ» ¸ÔÀº ÈÄ¿¡ ÀϾ´Â ÁõÈıºÀÌ´Ù. ¸íÄ¡ ºÎºÐÀÇ ÆØ¸¸°¨°ú ¾Ð¹Ú°¨-±¸¿ª-±¸Åä µîÀÇ º¹ºÎÁõ»ó ¿Ü¿¡ Å»·Â°¨-Çö±âÁõ-¹ßÇÑ-°¡½¿¶ê µî ¼øÈ¯Àå¾Ö Áõ»óÀÌ µû¸¥´Ù. ±×·± Áõ»óÀº ¼·ÃëÇÑ À½½Ä¹°ÀÌ À§¿¡¼­ ÀÛÀºÃ¢ÀڷΠÃß¶ôÇÏµí ¹èÃâµÊÀ¸·Î½á À½½Ä¹°ÀÇ ¹«°Ô·Î ÀÎÇØ ¼ÒÈ­°üÀÌ ¾Æ·¡ÂÊÀ¸·Î ÃÄÁ®µç´Ù. ÀÛÀºÃ¢ÀÚº®ÀÌ ±Þ°ÝÇϰԠ´Ã¾î³ªµç°¡, È­ÇÐÀû ÀÚ±ØÀ¸·Î ÀÎÇÑ ÀÛÀºÃ¢ÀÚº®ÀÇ ÀÚÀ²½Å°æ¹Ý»ç, ÀÛÀºÃ¢ÀÚº®ÀÇ »ïÅõ¾Ð¿¡ ÀÇÇØ ¼ÒÈ­°üÀ¸·Î ¼öºÐÀÌ ±Þ¼ÓÈ÷ ´ë·® À̵¿ÇÏ¿© ¼øÈ¯µÇ´Â Ç÷¾×ÀÇ ¾çÀÌ °¨¼ÒÇÏ¿© ÀϾ´Ù. ÁַΠ½Ä»ç¿ä¹ýÀ¸·Î Ä¡·áÇÏ¿©, ¾à¹°¿ä¹ýÀ¸·Î´Â ¾ÆÆ®·ÎÇÉ-Çí»ç¸ÞÅä´½-Æä³ë¹Ù¸£ºñÅ»-ź»ê¼ö¼Ò³ªÆ®·ýÀÇ »ç¿ë ¹× Æ÷µµ´çÁֻ絵 È¿°ú°¡ ÀÖ´Ù. ¼ö¼ú¿ä¹ýÀº ºô·Î½º(Billroth) Á¦1¹ýÀ¸·ÎÀÇ º¯È¯, ´ë¿ëÀ§ÀÇ Á¦ÀÛ µîÀÌ ÀÖÀ¸³ª È®½ÇÇÑ °ÍÀº ¾Æ´Ï´Ù.
¿µ¹® Raynaud syndrome ÇÑ±Û ·¹À̳ëÁõÈıº
¼³¸í   
  »çÁöÀÇ ´ëĪÀû Ã»»öÁõÀ» Æ¯Â¡À¸·Î Çϴ Áõ»óÀ¸·Î¼­ ¼Õ°¡¶ô-¼Õ¸ñ µîÀÇ ÇǺΰ¡ Áö¼ÓÀûÀ¸·Î Ã»»ö°ú Àû»öÀ¸·Î º¯Çϰí, ¼Õ°¡¶ôÀÇ ´ë·® ¶¡³²°ú ³Ã°¢À» ¼ö¹ÝÇÑ´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple abscess
    ¹µ°í¸§Áý, ´Ù¹ß³ó¾ç
  • multiple allele
    ¹µ¸Â¼¶À¯ÀüÀÚ, º¹¼ö´ë¸³À¯ÀüÀÚ
  • multiple birth
    ´Ùžƺи¸
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple division
    º¹Çպп­
  • multiple drug resistance
    ´Ù¾àÁ¦³»¼º, ¿©·¯¾àÀúÇ×
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple endocrine adenomatosis
    ´Ù¹ß¼º³»ºÐºñ»ùÁ¾Áõ
  • multiple endocrine neoplasia
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç
  • multiple endocrine neoplasia 1
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç1Çü
  • multiple endocrine neoplasia 2
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç2Çü
  • multiple endocrine neoplasia 3
    ´Ù¹ß³»ºÐºñ»ùÁ¾¾ç3Çü
  • multiple epiphyseal dysplasia
    ¹µ»À³¡Çü¼ºÀÌ»ó, ´Ù¹ß°ñ´ÜÇü¼ºÀÌ»ó
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Asherman's syndrome
    (¢¡ intrauterine synechia) ¾Æ¼Å¸¸ÁõÈıº
  • carpal tunnel syndrome
    ¼Õ¸ñ±¼ÁõÈıº, ¼ö±Ù°üÁõÈıº
  • cauda equina syndrome
    ¸»ÃÑÁõÈıº, ¸¶¹ÌÁõÈıº
  • compartment syndrome
    ±¸È¹ÁõÈıº
  • contact urticaria syndrome
    Á¢Ã˵ε巯±âÁõÈıº
  • cubital tunnel syndrome
    ÆÈ²ß±¼ÁõÈıº
  • Cushing's syndrome
    Äí½ÌÁõÈıº
  • dialysis disequilibrium syndrome
    Åõ¼®ºÒ±ÕÇüÁõÈıº
  • dry eye syndrome
    ´«¸¶¸§ÁõÈıº
  • dumping syndrome
    ºü¸¥ºñ¿òÁõÈıº, ´ýÇÎÁõÈıº
  • fetal alcohol syndrome
    žƾËÄÚ¿ÃÁõÈıº
  • Floppy infant syndrome
    Àú±äÀ徯ÁõÈıº, ±äÀåÀúÇÏ¿µ¾ÆÁõÈıº
  • Ganser syndrome
    °£ÀúÁõÈıº
  • Goodpasture's syndrome
    ±ÂÆÄ½ºÃ³ÁõÈıº
  • Guillain-Barre syndrome
    (¢¡acute idiopathic polyneuritis) ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿° , ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple allele
    ¹µ¸Â¼¶ÀÎÀÚ
  • multiple endocrine adenomatosis
    ´Ù¹ß³»ºÐºñ»ùÁ¾Áõ
  • multiple birth
    ´Ù»ê, ´ÙÅÂÃâ»ê, °æ»ê
  • multiple bond
    ´ÙÁß°áÇÕ
  • multiple character
    ´ÙÁß¼º°Ý
  • multiple correlation
    ´ÙÁß»ó°ü
  • multiple deformity
    º¹ÇÕ±âÇü
  • multiple division
    º¹Çպп­
  • multiple dysplasia
    ¹µÇü¼ºÀå¾Ö
  • multiple personality disorder
    ´ÙÁßÀΰÝÀå¾Ö
  • hereditary multiple exostosis
    À¯Àü´Ù¹ß»Àµ¹ÃâÁõ
  • multiple embolism
    ´Ù¹ß»öÀüÁõ
  • multiple epitheliomatosis
    ´Ù¹ß»óÇÇÁ¾Áõ
  • multiple excitation
    ¹Ýº¹ÈïºÐ
  • multiple fetation
    ´Ù¼öÀÓ½Å
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • Browns syndrome->superior oblique tendon sheath syndrome
    ºê¶ó¿îÁõÈıº
  • ICE syndrome=iridocorneal endothelial syndrome
    ȫä°¢¸·³»ÇÇÁõÈıº
  • Lowes syndrome->oculocerebrorenal syndrome
    ·Î¿ìÁõÈıº
  • PIE syndrome => pulmonary infiltration with eosinophilia syndrome
    È£»ê±¸Áõ°¡¼º ÆóħÀ± ÁõÈıº
  • Q-T prolongation syndrome ; long Q-T syndrome
    Q-T°£°Ý ¿¬ÀåÁõÈıº.
  • Raeders syndrome=>painful Horners syndrome
    ·¹ÀÌ´õÁõÈıº
  • Steiners syndrome [=curtius syndrome, facial hemi
    ¾È¸é¹Ý(ÂÊ)ºñ´ëÁõ
  • UGH syndrome->uveitis-glaucoma-hemorrhage syndrome
    À¯Áö¿¡ÀÌÃëÁõÈıº
  • A-V syndrome
    A-VÁõÈıº
  • Acquiered immune deficiency syndrome
    ÈÄõ¼º ¸é¿ª °áÇÌÁõÈıº
  • Adams Stokes syndrome
    ¾Ö´ý½º-½ºÅäÅ©½ºÁõÈıº.
  • Albrights syndrome
    ¾Ëºê¶óÀÌÆ® ÁõÈıº(~ ñøý¦ÏØ)
  • Alezzandrinis syndrome
    ¾Ë·¹Àܵ帮´ÏÁõÈıº
  • Alports syndrome
    ¾ËÆ÷Æ® ÁõÈıº
  • Alstr ms syndrome
    ¾Ë½ºÆ®·Ý ÁõÈıº
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • dose, lethal
    Ä¡»ç·®
  • granuloma, lethal midline
    ¾Ç¼º Á߽ɼ± ¼º À°¾ÆÁ¾
  • half lethal dose
    ¹ÝÄ¡»ç·®(ÚâöÈÞÝåÖ).
  • lethal
    Ä¡»ç
  • lethal coefficient
    Ä¡»ç°è¼ö(ÊÙË­Ëà).
  • lethal concentration
    Ä¡»ç³óµµ
  • lethal dose
    Ä¡»ç¼±·®
  • lethal dose
    Ä¡»ç·®
  • lethal gas
    Ä¡»ç°¡½º, µ¶(Ô¸)°¡½º.
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ(¡­ë¶îîí­).
  • lethal gene
    Ä¡»çÀ¯ÀüÀÚ
  • lethal midline granuloma
    ¾Ç¼ºÁß½É(¼º)À°¾ÆÁ¾
  • lethal midline granuloma
    Ä¡»ç¼º Á߽ɼ± À°¾ÆÁ¾
  • lethal midline granuloma
    Ä¡»ç¼ºÁ߽ɼ±À°¾ÆÁ¾(öÈÞÝàõñéãýàÊë¿ä´ðþ)
  • lethal mutant, conditional
    Á¶°ÇÄ¡»ç µ¹¿¬º¯ÀÌÁÖ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lethal mutation model
    Ä¡»çº¯ÀÌ(öÈÞÝܨì¶)¸ðµ¨
  • lethal synthesis
    Ä¡»çÇÕ¼º(öÈÞÝùêà÷)
  • median lethal dose
    Á¤Áß Ä¡»ç·®(ïáñéöÈÞÝÕá)
  • minbimum lethal dose
    ÃÖ¼ÒÄ¡»ç·®(õÌá³öÈÞÝÕá)
  • recessive lethal gene
    ¿­¼º Ä¡»çÀ¯ÀüÀÚ(Ö«àõöÈÞÝë¶îîí­)
  • Crigler-Najjar syndrome
    Å©¸®±Û·¯-³ª¾ß¸£ ÁõÈıº(ñøý¦ÏØ)
  • Down's syndrome
    ´Ù¿î ÁõÈıº(ñøý¦ÏØ) (ÔÒ) mongolism
  • ectopic hormone syndrome
    À̼Ò(ì¶á¶) È£¸£¸ó ÁõÈıº(ñøý¦ÏØ)
  • Fanconi's syndrome
    ÆÇÄÚ´Ï ÁõÈıº(ñøý¦ÏØ)
  • fragile X syndrome
    Ãë¾à(öªå°) X ÁõÈıº(ñøý¦ÏØ)
  • general adaptation syndrome
    ÀÏ¹Ý ÀûÀÀ ÁõÈıº(ìéÚõ îêëëñøý¦ÏØ)
  • Hunter's syndrome
    ÇåÅÍ ÁõÈıº(ñøý¦ÏØ)
  • Hurler's syndrome
    Çæ·¯ ÁõÈıº(ñøý¦ÏØ)
  • Lesch-Nyhan syndrome
    ·¹½¬-´ÏÇÑ ÁõÈıº(ñøý¦ÏØ)
  • Pendred's syndrome
    Ææµå·¹µå ÁõÈıº(ñøý¦ÏØ)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • multiple overlapping thin slab acquisition [=MOTSA]
    ´ÙÁßÁߺ¹¼¼ÆíÆÇȹµæ
  • multiple polyp
    ´Ù¹ß¼ºÆú¸³
  • multiple sclerosis
    ´Ù¹ß¼º°æÈ­Áõ
  • Banti's syndrome
    ¹ÝƼÁõÈıº
  • battered child syndrome
    ÇÇÇÐ´ë¾ÆÁõÈıº
  • Behcet's syndrome
    º£Ã¼Æ®ÁõÈıº
  • blind loop syndrome
    ¸Í°èÁ¦ÁõÈıº
  • cauda equina syndrome
    ¸¶¹ÌÁõÈıº
  • cord compression syndrome
    ô¼ö¾Ð¹ÚÁõÈıº
  • Cushing's syndrome
    Äí½ÌÁõÈıº
  • double crush syndrome
    ÀÌÁߺмâÁõÈıº
  • empty sella syndrome
    °øÅÍŰ¾ÈÁõÈıº
  • facet syndrome
    ôÃßÈİüÀýÁõÈıº
  • fetal distress syndrome
    žưï¶õÁõÈıº
  • gonadal dysgenesis; Turner's syndrome
    ¼º¼±À̹߻ýÁõ, ÅͳÊÁõÈıº
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
MLD manual lymph drainage; median lethal dose; metachromatic leukodystrophy; minimal lesion disease; min...
MCS malignant carcinoid syndrome; managed care system; massage of the carotid sinus; mesocaval shunt; me...
CS calf serum; campomelic syndrome; carcinoid syndrome; cardiogenic shock; caries-susceptible; carotid ...
PCS palliative care service; Patient Care System; patterns of care study; pelvic congestion syndrome; ph...
SBS shaken baby syndrome; short bowel syndrome; sick building syndrome; sinobronchial syndrome; small bo...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
LD50 Lethal dose
LD50 Lethal dose 50
LF Lethal factor
LMG Lethal mid-line granuloma
LT Lethal toxin
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • affecting multiple system
    ´Ù¹ß¼º °èÅëÀ» ħ¹üÇÑ
  • multiple
    ´Ù¹ß¼º, ´Ù¼öÀÇ
  • multiple abutment
    ´Ù¼ö Áö´ëÄ¡
  • multiple allelomorph
    º¹´ë¸³ À¯ÀüÀÚ
  • multiple anchorage
    º¹ÇÕ °íÁ¤
    1Çü½Ä ÀÌ»óÀÇ ÈûÀ» °¡ÇÏ´Â ÀåÄ¡¸¦ »ç¿ëÇÏ´Â °íÁ¤.
  • multiple angioma
    ´Ù¹ß¼º ¸Æ°üÁ¾
  • multiple biologically active peptide fragment
    ´Ù¹ß¼º »ý¹°ÇÐÀû Ȱ¼º ÆéŸÀÌµå ºÐÀý
  • multiple cavernous hemangioma
    ´Ù¹ß¼º ÇØ¸é Ç÷°üÁ¾
  • multiple condylome
    ´Ù¹ß¼º ½À¿ì
  • multiple cranial nerve palsy
    ´Ù¹ß¼º ³ú ½Å°æ ¸¶ºñ
  • multiple diagnosis
    º¹¼ö Áø´Ü
  • multiple drug misuse
    ¿©·¯ ¾à¹°ÀÇ ¿À¿ë
  • multiple drug resistance gene
    º¹ÇÕ ¾àÁ¦ ³»¼º À¯ÀüÀÚ
  • multiple endocrine neoplasia
    ´Ù¹ß¼º ³»ºÐºñ Á¾¾ç
  • multiple epiphyseal dysplasia
    ´Ù¹ß¼º °ñ´Ü ÀÌÇü¼ºÁõ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
granuloma, lethal midline A non-neoplastic disease of unknown aetiology beginning with inflammation, ulceration, and perforation of nose and palate and progressing to gradual destruction of midline facial structures.
(12 Dec 1998)
chicken embryo lethal orphan virus <virology> A virus with characteristics of adenovirus, and similar to quail bronchitis virus.
Synonym: chicken embryo lethal orphan virus.
(05 Mar 2000)
minimal lethal dose <pharmacology> The minimal dose of a toxic substance or infectious agent that is lethal, as assayed in various experimental animals (e.g., the least amount of diphtheria toxin that, on an average, kills a 250-g guinea pig within 96 hours after subcutaneous inoculation).
When followed by a subscript (generally "MLD50"), denotes the minimal dose that is lethal to a certain percentage (e.g., 50%) of animals so assayed, LD05.
See: lethal dose.
(05 Mar 2000)
clinical lethal A disorder that culminates in premature death.
(05 Mar 2000)
conditional-lethal mutant A viral mutant that can replicate under some (permissive) conditions but not under other (restrictive or nonpermissive) conditions, the parent (wild type) strain being able to replicate under both conditions.
See: suppressor-sensitive mutant, temperature-sensitive mutant.
Synonym: conditional-lethal mutant.
(05 Mar 2000)
conditionally lethal mutant A viral mutant that can replicate under some (permissive) conditions but not under other (restrictive or nonpermissive) conditions, the parent (wild type) strain being able to replicate under both conditions.
See: suppressor-sensitive mutant, temperature-sensitive mutant.
Synonym: conditional-lethal mutant.
(05 Mar 2000)
dominant lethal trait Trait, expressed in the phenotype if present in the genotype, that precludes having descendants. All such cases are necessarily sporadic and must represent new mutations as the usual methods of classical genetics provide no means of demonstrating any genetic component whatsoever, except for tenuous arguments such as advanced paternal age. Molecular biology may help although the methods may be tedious; if there is an epistatic gene that may mask the trait, the logic is more tractable, though complex.
(05 Mar 2000)
y-suppressed lethal gene <genetics> In the fruit fly Drosophila, this is a recessive, lethal gene that kills XO flies but not normal XY male flies.
(09 Oct 1997)
zygotic lethal gene <genetics> A mutated or otherwise defective gene at embryonic or larval stages.
(06 May 1997)
lethal Deadly, fatal.
Origin: L. Lethalis, from lethum = death
(18 Nov 1997)
lethal coefficient <microbiology> That concentration of disinfectant that kills bacteria at 20-25°C in the shortest period of time.
(05 Mar 2000)
lethal dose <pharmacology> The amount, or dosage, of a toxin necessary to cause death.
(16 Mar 1998)
lethal dose 50 <pharmacology> The amount, or dosage, of a toxin necessary to kill 50% of the experimental subjects.
(16 Mar 1998)
lethal dwarfism Dwarfism leading to intrauterine or neonatal death.
(05 Mar 2000)
lethal equivalent A combination of selective effects that on average have the same impact on the composition of the gene pool as one death; e.g., two carriers at 50% risk of dying would be the lethal equivalent of one carrier at 100% risk, in the population genetics of recessive traits lethal equivalent is expressed as twice the sum of the expected number of deaths ascribable to the genetic load.
Expression used of the genetic load of recessive genes in heterozygous state that if in homozygous state would cause death or carry a risk of death. The expected number of deaths from all such genes is expressed in lethal equivalent.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 4 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • postvietnam syndrome
    º£Æ®³² ÈÄ ÁõÈıº
  • premenstrual syndrome
    ¿ù°æÀü ÁõÈıº
  • respiratory distress syndrome
    (½Å»ý¾ÆÀÇ)È£Èí Àå¾Ö ÁõÈıº
  • syndrome
    ÁõÈıº;ÇൿÇü
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á